Market Place
Sourcing Support
Marc Y. Joins Olatec’s Advisory Board As Immuno-Endocrinologist
28 Jan 2025 //
BUSINESSWIRE
First Patient Enrolled In Phase 2 Study Of Olatec`s Dapansutrile For Diabetes
11 Jul 2024 //
PR NEWSWIRE
Olatec to Conduct a Phase 2 Trial with its NLRP3 Inhibitor, Dapansutrile
20 Feb 2024 //
BUSINESSWIRE
Olatec Announces Publication of Research on Oral NLRP3 Inhibitor Dapansutrile
03 Oct 2023 //
BUSINESSWIRE
Olatec Therapeutics Announces the Completion of First Dose Cohort
16 May 2023 //
BUSINESSWIRE
Olatec Therapeutics Awarded a Grant from The Michael J. Fox Foundation
10 Mar 2023 //
BUSINESSWIRE
Olatec Announces the Final Closing, Led by Sanders Morris Harris
23 Feb 2023 //
BUSINESSWIRE
Craig T. Basson, MD, PhD Joins Olatec Therapeutics’ Board of Directors
16 Aug 2022 //
BUSINESSWIRE
HMP Partners Invests in Tevogen Bio™
15 Mar 2022 //
BUSINESSWIRE
Olatec Announces High-Impact Coverage of Dapansutrile
15 Feb 2022 //
BUSINESSWIRE
Olatec Therapeutics Announces Results Showing Dapansutrile Reduces
28 Apr 2021 //
BUSINESSWIRE
Olatec Therapeutics Announces a Scientific Publication on the Positive Results
11 Feb 2021 //
ARGUS-PRESS
Olatec Therapeutics Announces a Scientific Publication on the Positive Results
11 Feb 2021 //
BUSINESSWIRE
Olatec Therapeutics’ Dapansutrile, a Selective NLRP3 Inhibitor
29 Dec 2020 //
BUSINESSWIRE
Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.